Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.

David Allen BarringtonCrystal TubbsHaller J SmithJ Michael StraughnLeigha SenterDavid E Cohn

Published in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)

For patients with newly diagnosed ovarian cancer, maintenance therapy with niraparib was cost effective. Cost effectiveness was improved when analyzing those patients with homologous recombination deficiency and BRCA mutations. Efforts should continue to optimize poly-ADP-ribose polymerase utilization strategies.

Keyphrases

newly diagnosed
dna repair
dna damage
replacement therapy
oxidative stress
mesenchymal stem cells
bone marrow
smoking cessation
breast cancer risk
data analysis